News

According to the company, the Obagi Rosaclear System is the first and only complete prescription-based system developed specifically for treating the signs and symptoms of rosacea. The all-in-one

The small proof-of-concept diabetic vitrectomy (DV) trial has been enrolling slowly due to newer surgical procedures that have resulted in a decreasing number of vitrectomy procedures in the

The special protocol assessment (SPA) provides an agreement between the FDA and Seattle Genetics regarding the design, including size and clinical endpoints, of the pivotal trial to support

Under the terms of the agreement, Sysmex and Epigenomics will assess the suitability of Sysmex’s molecular diagnostics instrumentation for the detection of DNA methylation cancer biomarkers in blood.

The trials, known as the Gemini program, will study vedolizumab for the treatment of ulcerative colitis and Crohn’s disease, the two main types of inflammatory bowel disease (IBD).

The application, filed by Scolr on August 5, 2008, seeks approval to market a 120mg 12 hour pseudoephedrine tablet based on its patented Controlled Delivery Technology (CDT) platform.

Under the terms of the agreement S*BIO is eligible to receive up to $112.5 million in payments. This includes an upfront fee, development and sales milestone payments and

The double-blinded, randomized, placebo-controlled, dose ranging study is designed to evaluate the drug in about 180 pre-menopause obese women. The study is intended to confirm and extend previous

In this study, the therapeutic efficacy of SN-38 conjugated to labetuzumab was evaluated in two animal models of human colon cancer. Labetuzumab is a non-internalizing humanized antibody that